natgillin/translations-raw huggingface dataset:
In the event of any sudden visual defect, the treatment should be stopped immediately and alternative treatment should be considered (see section 4.3).
U slučaju iznenadnog poremećaja vida liječenje lijekom Revatio je potrebno odmah prekinuti i razmotriti alternativno liječenje (vidjeti dio 4.3).
In the event of blocked needle, the patients must follow the instructions described in Step 3 of the Instructions for Use accompanying the package leaflet (see section 4.2).
U slučaju začepljenja igle, bolesnici se moraju pridržavati uputa opisanih u 3. koraku Uputa za uporabu, koje dolaze zajedno s Uputom o lijeku (vidjeti dio 4.2).
In the event of bradycardia with poor haemodynamic tolerance, symptomatic treatment including intravenous beta- stimulating medicinal products such as isoprenaline may be considered.
U slučaju bradikardije sa slabom hemodinamskom tolerancijom, može se razmotriti mogućnost simptomatskog liječenja koje uključuje intravensku primjenu stimulatora betaadrenergičnih receptora, kao što je izoprenalin.
In the event of clinical signs of adverse reactions or overdose of clobazam (i.e., drowsiness, hypotonia, and irritability in young children), this daily dose was reduced by 25% every week.
U slučaju kliničkih znakova nuspojava ili predoziranja klobazamom (to jest, pospanosti, hipotonije, te razdražljivosti u male djece), ova dnevna doza je umanjivana svakog tjedna za 25%.
In the event of contact with the eyes, irrigate with large amounts of water.
U slučaju kontakta s očima, isperite obilnim količinama vode.
In the event of contact, the area should be irrigated with plenty of water for at least 15 minutes.
U slučaju kontakta isperite područje s mnogo vode najmanje 15 minuta.
In the event of decreased platelet count to Grade 3 or greater (< 50,000/mm3), do not administer trastuzumab emtansine until platelet counts recover to Grade 1 (≥ 75,000/mm3) (see section 4.2).
U slučaju smanjenja broja trombocita stupnja 3 ili višeg (< 50 000/mm3), trastuzumab emtanzin se ne smije primijeniti dok se broj trombocita ne vrati na vrijednost stupnja 1 (≥ 75 000/mm3) (vidjeti dio 4.2).
In the event of deterioration of COPD during treatment with Hirobriz Breezhaler, a re- evaluation of the patient and of the COPD treatment regimen should be undertaken.
Ako dođe do pogoršanja KOPB-a tijekom liječenja Hirobriz Breezhalerom, bolesnika treba ponovno pregledati i provesti liječenje KOPB-a.
In the event of deterioration of COPD during treatment with Onbrez Breezhaler, a re- evaluation of the patient and of the COPD treatment regimen should be undertaken.
Ako dođe do pogoršanja KOPB-a tijekom liječenja Onbrez Breezhalerom, bolesnika treba ponovno pregledati i provesti liječenje KOPB-a.
In the event of deterioration of COPD during treatment with umeclidinium bromide, a re-evaluation of the patient and of the COPD treatment regimen should be undertaken.
U slučaju pogoršanja KOPB-a tijekom liječenja umeklidinijevim bromidom, treba ponovno procijeniti stanje bolesnika i režim liječenja KOPB-a.
In the event of early regurgitation, identify the animal by matching the animal ID number with the number on the intraruminal device and re-administer an undamaged intraruminal device.
U slučaju prijevremene regurgitacije naprave, identificirajte životinju usporedbom identifikacijskog broja životinje i broja na intraruminalnoj napravi i ponovno primijenite neoštećenu intraruminalnu napravu.
In the event of either being observed, discard the vaccine.
Ako se primijeti bilo što od toga dvoje, cjepivo se ne smije upotrijebiti.
In the event of either being observed, discard the vaccine.
Ako se primijeti nešto od toga, cjepivo se ne smije upotrijebiti.
In the event of either being observed, discard the vaccine.
U slučaju da primijetite nešto od spomenutog, bacite cjepivo.
In the event of either being observed, discard the vaccine.
U slučaju uočavanja promjena ili stranih čestica cjepivo treba baciti.
In the event of either being observed, discard the vaccine.
U slučaju uočavanja promjena ili stranih čestica, cjepivo treba baciti.
In the event of either being observed, discard the vaccine.
U slučaju uočavanja takvih pojava, odbacite cjepivo.
In the event of grade 2-4 acute toxicity, treatment must be discontinued immediately .
U slučaju akutne toksičnosti 2.-4. stupnja liječenje se mora odmah prekinuti.
In the event of haemorrhagic complications, treatment must be discontinued and the source of bleeding investigated.
U slučaju hemoragičkih komplikacija liječenje se mora prekinuti, a izvor krvarenja treba ispitati.
In the event of haemorrhagic complications, treatment must be discontinued and the source of bleeding investigated.
U slučaju hemoragičkih komplikacija, liječenje se mora prekinuti, a izvor krvarenja treba ispitati.
In the event of human exposure to the active ingredient of the vaccine, seek medical advice immediately and show the package leaflet i or the label to the physician.
U slučaju izloženosti osoba djelatnom sastojku cjepiva, odmah potražiti pomoć liječnika i pokažite mu uputu o VMP ili etiketu.
In the event of human exposure to the active ingredient of the vaccine, seek medical advice immediately and show the package leafletor the label to the physician.
U slučaju izloženosti osoba djelatnom sastojku cjepiva, odmah potražiti pomoć liječnika i pokažite mu uputu o VMP ili etiketu.
In the event of isolated bronchospasm, treatment must be permanently discontinued.
U slučaju izoliranog bronhospazma, tretman se mora trajno prekinuti.
In the event of neurotoxicity, the recommended dose adjustment for ALIMTA and cisplatin is documented in Table 3.
Preporučena prilagodba doze lijeka ALIMTA i cisplatina u slučaju neurotoksičnosti navedena je u Tablici 3.
In the event of neurotoxicity, the recommended dose adjustment for CIAMBRA and cisplatin is documented in Table 3.
Preporučena prilagodba doze lijeka CIAMBRA i cisplatina u slučaju neurotoksičnosti navedena je u Tablici 3.
In the event of neurotoxicity, the recommended dose adjustment for Pemetrexed Accord and cisplatin is documented in Table 3.
Preporučena prilagodba doze lijeka Pemetrexed Accord i cisplatina u slučaju neurotoksičnosti navedena je u Tablici 3.
In the event of neurotoxicity, the recommended dose adjustment for pemetrexed and cisplatin is documented in Table 3.
Preporučena prilagodba doze pemetrekseda i cisplatina u slučaju neurotoksičnosti navedena je u Tablici 3.
In the event of neurotoxicity, the recommended dose adjustment for Pemetrexed Fresenius Kabi and cisplatin is documented in Table 3.
Preporučena prilagodba doze lijeka Pemetrexed Fresenius Kabi i cisplatina u slučaju neurotoksičnosti navedena je u Tablici 3.
In the event of neurotoxicity, the recommended dose adjustment for Pemetrexed Hospira and cisplatin is documented in Table 3.
Preporučena prilagodba doze lijeka Pemetreksed Hospira i cisplatina u slučaju neurotoksičnosti navedena je u Tablici 3.
In the event of neurotoxicity, the recommended dose adjustment for Pemetrexed Lilly and cisplatin is documented in Table 3.
Preporučena prilagodba doze lijeka Pemetrexed Lilly i cisplatina u slučaju neurotoksičnosti navedena je u Tablici 3.
In the event of neurotoxicity, the recommended dose adjustment for Pemetrexed Sandoz and cisplatin is documented in Table 3.
Preporučena prilagodba doze lijeka Pemetrexed Sandoz i cisplatina u slučaju neurotoksičnosti navedena je u Tablici 3.
In the event of other variation being observed, discard the vaccine.
U slučaju da primijetite nekakvo odstupanje od navedenog, bacite cjepivo.
In the event of other variation being observed, discard the vaccine.
U slučaju da primijetite nekakvo odstupanje, bacite cjepivo.
In the event of overdosage there may be an increased risk of bleeding.
U slučaju predoziranja može doći do povećanog rizika od krvarenja.
In the event of overdose, appropriate supportive treatment (possibly given parenterally) should be initiated according to the patient’s clinical signs and symptoms.
U slučaju predoziranja treba započeti odgovarajuće potporno liječenje (po mogućnosti parenteralno) u skladu s bolesnikovim kliničkim znakovima i simptomima.
In the event of overdose, appropriate supportive treatment should be initiated according to the patient’s clinical signs and symptoms.
U slučaju predoziranja treba započeti odgovarajuće potporno liječenje prema bolesnikovim kliničkim znakovima i simptomima.
In the event of overdose, appropriate supportive treatment should be initiated according to the patient’s clinical signs and symptoms.
U slučaju predoziranja treba započeti odgovarajuće potporno liječenje u skladu s bolesnikovim kliničkim znakovima i simptomima.
In the event of overdose, appropriate supportive treatment should be initiated according to the patient’s clinical signs and symptoms.
U slučaju predoziranja, potrebno je uvesti odgovarajuće potporno liječenje u skladu s bolesnikovim kliničkim znakovima i simptomima.
In the event of overdose, general supportive measures should be initiated based on the patient’s signs and symptoms.
U slučaju predoziranja potrebno je započeti s općim suportivnim mjerama na temelju postojećih znakova i simptoma kod bolesnice.
In the event of overdose, it is recommended that appropriate supportive treatment be initiated, as dictated by the patient’s clinical status, until resolution of the symptoms.
U slučaju predoziranja, preporučuje se započinjanje odgovarajućeg potpornog liječenja, u skladu s bolesnikovim kliničkim statusom, do povlačenja simptoma.
In the event of overdose, patients should be monitored for signs and symptoms of hypocalcaemia, and treatment should be symptomatic and supportive.
U slučaju predoziranja, bolesnike se mora nadzirati zbog znakova i simptoma hipokalcemije a liječenje mora biti potporno i simptomatsko.
In the event of overdose, treatment should be supportive and directed toward alleviating symptoms.
U slučaju predoziranja treba uvesti potporno liječenje usmjereno prema ublažavanju simptoma.
In the event of phenylephrine overdose, prompt injection of a rapidly acting alpha-adrenergic blocking agent, such as phentolamine, has been recommended.
U slučaju predoziranja fenilefrinom, preporučeno je bez odlaganja primijenti injekciju brzodjelujućeg alfa- adrenegičkog blokatora, poput fentolamina.
In the event of polycythaemia, Aranesp should be temporarily withheld (see section 4.2).
U slučaju policitemije, uzimanje Aranespa mora se privremeno prekinuti (vidjeti dio 4.2.).
In the event of pregnancy following Zalmoxis treatment adverse effect on pregnancy and the developing foetus are not expected as lymphocytes do not pass the placenta.
U slučaju trudnoće nakon liječenja Zalmoxisom, ne očekuju se štetni učinci na trudnoću i razvoj fetusa budući da limfociti ne prelaze posteljicu.
In the event of rapidly elevating transaminase levels (ALT/AST, > 5 times upper limit of normal, ULN), discontinuation of Zerit and any potentially hepatotoxic medicinal products should be considered.
U slučaju brzog porasta razina transaminaza (ALT/AST > 5 puta iznad gornje granice normalnih vrijednosti, ULN) treba razmotriti prekid primjene lijeka Zerit i potencijalno hepatotoksičnih lijekova.
In the event of recurrence of ANC
U slučaju da je ABN ponovno
In the event of recurrence of ANC
U slučaju da je ABN ponovno <1,0 x109/l
In the event of recurrence of ANC < 1.0 x 109/l and/or platelets < 50 x 109/l, repeat step 1 and resume imatinib at reduced dose of 400 mg.
U slučaju da je ABN ponovno <1,0 x 109/l i/ili trombociti <50 x 109/l, treba ponoviti 1. korak i nastaviti primjenu imatiniba u smanjenoj dozi od 400 mg.
In the event of recurrence of ANC < 1.0 x109/l and/or platelets < 50 x109/l, repeat step 1 and resume imatinib at reduced dose of 260 mg/m2.
U slučaju da je ABN ponovno <1,0 x109/l i/ili trombociti <50 x109/l, treba ponoviti 1. korak i nastaviti primjenu imatiniba u smanjenoj dozi od 260 mg/m².
In the event of severe and perisistent diarrhoea, Rasilez HCT therapy should be stopped (see section 4.8).
U slučaju teškog i ustrajnog proljeva, potrebno je prekinuti terapiju Rasilez HCT-om (vidjeti dio 4.8).
In the event of severe and persistent diarrhoea, Rasilamlo therapy should be stopped (see section 4.8).
U slučaju teškog i ustrajnog proljeva potrebno je prekinuti terapiju lijekom Rasilamlo (vidjeti dio 4.8).
In the event of severe and persistent diarrhoea, Rasilez therapy should be stopped (see section 4.8).
U slučaju teškog i ustrajnog proljeva potrebno je prekinuti terapiju Rasilezom (vidjeti dio 4.8).
In the event of severe or persistent diarrhoea, nausea, anorexia, or vomiting associated with dehydration, Tarceva therapy should be interrupted and appropriate measures should be taken to treat the dehydration (see section 4.8).
U slučaju teškog ili dugotrajnog proljeva, mučnine, anoreksije ili povraćanja uz dehidraciju, potrebno je obustaviti terapiju lijekom Tarceva i poduzeti odgovarajuće mjere za liječenje dehidracije (vidjeti dio 4.8).
In the event of significant worsening, labile or treatment-resistant hypertension, interrupt treatment and consider evaluating for renal artery stenosis.
U slučaju značajnog pogoršanja hipertenzije, granične ili refraktorne hipertenzije odmah prekinite liječenje i razmotrite dijagnostičku obradu zbog suspektne stenoze bubrežne arterije.
In the event of symptoms women should be advised to seek urgent medical attention and to inform the healthcare professional that she is taking a CHC.
U slučaju simptoma, ženama treba savjetovati da odmah potraže medicinsku pomoć i obavijeste liječnika da uzimaju kombinirani hormonski kontraceptiv.
In the event of this happening treatment with Peyona should be stopped immediately and your baby’s doctor should treat the overdose.
U to slučaju treba odmah prekinuti liječenje lijekom Peyona, a liječnik Vašeg djeteta treba liječiti predoziranje.
In the event of unexplained and clinically significant weight loss, these patients should be evaluated by a medical practitioner and discontinuation of treatment should be considered.
U slučaju neobjašnjenog i klinički značajnog gubitka težine, te bolesnike treba procijeniti liječnik i valja razmotriti prekid liječenja.
In the event that a patient already receiving olaparib requires treatment with a P-gp inhibitor, careful monitoring of olaparib associated adverse events and management of those events via the dose reduction strategy is recommended (see section 4.2).
U slučaju da bolesnica koja već prima olaparib treba liječenje inhibitorom P-gp-a, preporučuje se pažljiv nadzor zbog moguće pojave nuspojava povezanih s primjenom olapariba, kao i zbrinjavanje tih nuspojava strategijom smanjenja doze (vidjeti dio 4.2).
In the event that a patient already receiving olaparib requires treatment with a strong CYP3A inducer, the prescriber should be aware that the efficacy of olaparib may be substantially reduced (see section 4.5).
U slučaju da je bolesniku koji već prima olaparib potrebno liječenje sa snažnim induktorom CYP3A, propisivač mora biti svjestan da djelotvornost olapariba može biti značajno smanjena (vidjeti dio 4.5).
In the event that any of the following observations are made following the application/overdose of the veterinary medicinal product, reversal should be initiated: severe sedation, unconsciousness, seizures, laboured or abdominal breathing or severe hypotension.
U slučaju da primijetite bilo koji od sljedećih događaja nakon primjene/predoziranja veterinarsko- medicinskog proizvoda, potrebno je započeti oporavak : ozbiljna sedacija, nesvjestica, epileptički napadaji, otežano ili abdominalno disanje ili teška hipotenzija.
In the event that co-administration of clofazimine with bedaquiline is necessary, clinical monitoring including frequent electrocardiogram assessment is recommended (see section 4.5).
U slučaju da je neophodna istovremena primjena klofazimina s bedakilinom, preporučeno je kliničko praćenje uključujući čestu procjenu elektrokardiograma (vidjeti dio 4.5).
In the event that co-administration of such medicinal products with bedaquiline is necessary, clinical monitoring including frequent electrocardiogram assessment is recommended.
U slučaju da je istovremena primjena takvih lijekova s bedakilinom neophodna, preporučeno je kliničko praćenje uključujući čestu procjenu elektrokardiograma.
In the event that commercially manufactured oseltamivir powder for oral suspension is not available, the pharmacist may compound a suspension (6 mg/ml) from Ebilfumin capsules or patients can prepare the suspension from capsules at home.
Kada tvornički proizveden oseltamivir prašak za oralnu suspenziju nije dostupan, bolesnici koji ne mogu progutati kapsule mogu uzimati odgovarajuće doze Ebilfumin pripravka pripremljenog u ljekarni ili kod kuće.
In the event that oseltamivir powder for oral suspension is not available, the pharmacist may compound a suspension (6 mg/ml) from Ebilfumin capsules.
U slučaju kada oseltamivir prašak za oralnu suspenziju nije dostupan, ljekarnik može pripremiti suspenziju (6 mg/ml) iz Ebilfumin kapsula.
In the event that oseltamivir powder for oral suspension is not available, the pharmacist may compound a suspension (6 mg/ml) from Ebilfumin capsules.
U slučaju kada prašak oseltamivira za oralnu suspenziju nije dostupan, ljekarnik može pripremiti suspenziju (6 mg/ml) iz kapsula Ebilfumina.
In the event that serum calcium levels fall below 8.4 mg/dl (2.1 mmol/l) and/or symptoms of hypocalcaemia occur the following management is recommended:
U slučaju da vrijednosti serumskog kalcija padnu ispod 8,4 mg/dl (2,1 mmol/l), i/ili nastupe simptomi hipokalcemije, preporuča se sljedeće liječenje:
In the event that you have moderate or severe kidney problems, your doctor will reduce your dose to 400 mg once daily for moderate kidney problems and to 300 mg once daily for severe kidney problems.
U slučaju umjerenih ili teških problema s bubrezima, Vaš liječnik će Vam smanjiti dozu na 400 mg jednom dnevno kod umjerenih problema s bubrezima i na 300 mg jednom dnevno kod teških problema s bubrezima.
In the event-triggered analysis, vaccine efficacy against CIN1 associated with HPV 16/18 observed in the ATP cohort was 94.1% (96.1% CI: 83.4;98.5).
U događajem potaknutoj analizi, djelotvornost cjepiva protiv CIN1 povezanim sa HPV 16/18, uočena u ATP kohorti, bila je 94,1% (96,1% CI: 83,4;98,5).
In the example above the dose number shows there are 13 injections left
U gornjem primjeru broj doze pokazuje da je preostalo još 13 injekcija.
In the extension phase of these studies, which lasted up to 52 weeks, there was an increase in HbA1c in both the duloxetine and routine care groups, but the mean increase was 0.3% greater in the duloxetine- treated group.
U produženoj fazi tih ispitivanja, koje je trajalo do 52 tjedna, HbA1c se povećao i u skupini liječenoj duloksetinom i u skupinama bolesnica na standardnom liječenju, ali je srednja vrijednost bila za 0,3% veća u skupini liječenoj duloksetinom.
In the extension phase of these studies, which lasted up to 52 weeks, there was an increase in HbA1c in both the duloxetine and routine care groups, but the mean increase was 0.3% greater in the duloxetine- treated group.
U produženoj fazi tih ispitivanja, koje je trajalo do 52 tjedna, HbA1c se povećao i u skupini liječenoj duloksetinom i u skupinama bolesnika na standardnom liječenju, ali je srednja vrijednost bila za 0,3% veća u skupini liječenoj duloksetinom.
In the extension phase of these studies, which lasted up to 52 weeks, there was an increase in HbA1c in both the duloxetine and routine care groups, but the mean increase was 0.3% greater in the duloxetine- treated group.
U produžetku tih ispitivanja, koje je trajalo do 52 tjedna, HbA1c se povećao i u skupini liječenoj duloksetinom i u skupini bolesnika na standardnom liječenju, ali je srednja vrijednost porasta bila za 0,3% veća u skupini koja je primala duloksetin.
In the extension study, similar numbers of patients taking Fosavance 70 mg/2,800 IU and Fosavance 70 mg/5,600 IU had low vitamin D levels (below 6%), but the patients taking Fosavance 70 mg/5,600 IU had greater increases in vitamin D levels over the 24 weeks of the study.
U produljenom ispitivanju, podjednak broj bolesnica koje su uzimale lijek Fosavance 70mg/2 800 IU i Fosavance 70 mg/5 600 IU imao je niske koncentracije vitamina D (manje od 6 %), no bolesnice koje su uzimale Fosavance 70 mg/5 600 IU imale su veća povećanja koncentracije vitamina D tijekom razdoblja ispitivanja od 24 tjedna.
In the extension study, similar numbers of patients taking Vantavo 70 mg/2,800 IU and Vantavo 70 mg/5,600 IU had low vitamin D levels (below 6%), but the patients taking Vantavo 70 mg/5,600 IU had greater increases in vitamin D levels over the 24 weeks of the study.
U proširenom ispitivanju, sličan broj bolesnica koje su uzimale lijekove Vantavo od 70 mg/2 800 IU i Vantavo 70 mg/5 600 IU imalo je nisku koncentraciju vitamina D (nižu od 6%), no bolesnice koje su uzimale lijek Vantavo 70 mg/5 600 IU imale su veće povećanje u koncentracijama vitamina D tijekom 24 tjedna ispitivanja.
In the eye, prostaglandins increase the
Prostaglandin u oku povećava drenažu tekućine (otjecanje očne
In the Eylea group the proportion of perfused patients was maintained through week 52).
U skupini liječenoj lijekom Eylea udio bolesnika s perfuzijom zadržan je do 52. tjedna.
In the F1 offspring, at the same dose level, mean body weights were reduced from birth until terminal sacrifice and the number of litters achieving criterion for preputial separation was slightly decreased.
U F1 potomstva, pri istoj dozi, smanjile su se srednje tjelesne težine od poroda sve do konačnog žrtvovanja, a broj okota koji su postigli kriterij za prepucijsku separaciju bio je malo smanjen.
In the fasted state there was no significant difference in the extent of absorption, as measured by the area under the plasma concentration-time curve (AUC) and maximal peak concentration (Cmax), of each component.
Na temelju površine pod krivuljom koncentracije u plazmi u ovisnosti o vremenu (AUC) i maksimalne koncentracije (Cmax) zaključeno je da natašte nema značajne razlike u opsegu apsorpcije svake komponente.
In the female and black subgroups which represented 32 % and 26 % of the overall study population respectively, a renal benefit was not evident, although the confidence intervals do not exclude it.
U podskupinama žena i pripadnika crne rase, koji su činili 32% odnosno 26% ukupne populacije u studiji, nisu bili vidljivi povoljni učinci na bubrege, premda to intervali pouzdanosti nisu isključivali.
In the female and black subgroups which represented 32% and 26% of the overall study population respectively, a renal benefit was not evident, although the confidence intervals do not exclude it.
U podskupinama žena i pripadnika crne rase, koji su činili 32% odnosno 26% ukupne populacije u studiji, nisu bili vidljivi povoljni učinci na bubrege, premda to intervali pouzdanosti nisu isključivali.
In the field study 98.5% of vaccinated cattle sampled (range 269–274 animals) developed antibodies to both BVD virus types.
U terenskom ispitivanju 98,5% od cijepljenje stoke koje su uzorkovane (raspon 269–274 životinja) razvilo je protutijela na oba tipa BVD virusa.
In the FIELD study, a randomised placebo-controlled trial performed in 9795 patients with type 2 diabetes mellitus, a statistically significant increase in pancreatitis cases was observed in patients receiving fenofibrate versus patients receiving placebo (0.8% versus 0.5%; p=0.031).
U randomiziranom, placebom kontroliranom ispitivanju "FIELD", provedenom na 9795 bolesnika s šećernom bolešću tipa 2, opažen je statistički značajno povećanje broja slučajeva pankreatitisa kod bolesnika koji su primali fenofibrat naspram bolesnika koji su primali placebo (0,8% naspram 0,5%; p=0,031).